Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
In this edition of Device Week, Medtech Insight’s Catherine Longworth chats to Marion Webb about two new major partnerships signed in the diabetes sector, and finds out more about ResMed’s growth strategy.
Israeli firm DreaMed has scored a new US Food and Drug Administration clearance for its AI-based diabetes decision support system Advisor Pro. The clearance enables physicians to use the software for patients with type 1 diabetes using continuous glucose monitoring (CGMs) and blood glucose meters (BGMs).
UK robotics firm CMR Surgical has landed $240m from investors as it prepares to launch its robotic surgery system in Europe and India. The Series C raise is Europe’s largest private financing round in the medical technology sector to date.
Abbott and Sanofi are partnering up to develop a new connected diabetes device. The non exclusive collaboration will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens and software currently under development.
The US FDA cleared a smartphone-based urine test for diagnosing chronic kidney disease. Israeli company Healthy.io developed the digital testing kit that enables smartphone cameras to act as clinical grade medical devices.
Baxter International is buying Israeli company Cheetah Medical in a $230m deal. The acquisition expands Baxter’s portfolio of medication delivery products.